Inhaled nitric oxide: Completed Phase II enrollment

Bellerophon completed enrollment of 159 patients with pulmonary hypertension associated with COPD in a double-blind, placebo-controlled, U.S. Phase II trial evaluating inhaled NO with INOpulse as add-on therapy. The product has Orphan Drug designation in the U.S. to treat pulmonary arterial hypertension (PAH). ...